openPR Logo
Press release

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics -

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.

Download the sample report @ https://www.pharmaproff.com/request-sample/1090

FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two types; primary and secondary FSGS, and can be treated using corticosteroids, ACE inhibitors, immunosuppressive drugs, diuretics, and diet modification.

Get the detailed analysis @ https://www.pharmaproff.com/report/fsgs-therapeutics-pipeline-analysis

Retrophin Inc. is in the process of developing Sparsentan, with dual mechanism of action that combines angiotensin receptor blockade with endothelin receptor blockade for the treatment of FSGS. Some other companies in FSGS pipeline are Variant Pharmaceuticals Inc. and ChemoCentryx Inc.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1090

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018 here

News-ID: 1742263 • Views: 393

More Releases for FSGS

Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Business Opportunitie …
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market DataIntelo, 13032020: The research report on the Focal Segmental Glomerulosclerosis (FSGS) Treatment Market is a deep analysis of the market. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight. Furthermore, the statistical survey in the report focuses on product specifications,
Focal Segmental Glomerulosclerosis (FSGS) Market: Launch of Pipeline Products in …
Focal segmental glomerulosclerosis Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on
Global Focal Segmental Glomerulosclerosis (FSGS) Market to Grow at 8% CAGR throu …
A new comprehensive study titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” has recently been added to the vast database of Market Research Reports Search Engine (MRRSE). The global focal segmental glomerulosclerosis (FSGS) market is likely to grow at a CAGR of 8% during the assessment period, and surpass US$ 15 Bn in terms of revenues. Download Sample Copy in a PDF
Global Focal Segmental Glomerulosclerosis (FSGS) Market: Industry Development Sc …
Market Research Report Search Engine (MRRSE) recently announced the addition of a new research study to its comprehensive collection of research reports. The research report, titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” offers a detailed analysis of the market providing insights into the market dynamics that are expected to influence the overall market positively in the next few years. Furthermore,
Focal Segmental Glomerulosclerosis (FSGS) Market: Comprehensive Analysis and Fut …
A latest research report titled as “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025”. has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or
Global Focal Segmental Glomerulosclerosis (FSGS) Market Anticipated to Surge at …
New research report offers a comprehensive analysis of the “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market. Request to view Sample Report @ https://www.mrrse.com/sample/4351 Global Focal segmental glomerulosclerosis (FSGS) Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients